Upcoming Deadline for ImmunityBio Investors: Important Class Action Details

Faruqi & Faruqi, LLP Investigates ImmunityBio If you invested in ImmunityBio, Inc. (NASDAQ: IBRX) between January 19 and March 24, 2026, you might be eligible for participation in a federal securities class action. Faruqi & Faruqi, LLP, a prominent national securities law firm, is actively investigating potential claims against ImmunityBio and reminds investors about the class action deadline set for May 26, 2026. This legal action centers around accusations that the company and its executives may have breached federal securities regulations by disseminating false and misleading information about their product capabilities, particularly concerning Anktiva, a promising drug intended for treating certain cancers. The law firm highlights the potential damages investors may have incurred, emphasizing the urgency for affected shareholders to act promptly. ## Background of the Case Recent developments indicate that on January 23, 2026, ImmunityBio released an announcement concerning updated Phase 2 clinical results from a study evaluating a new immunotherapy regimen for patients with glioblastoma. However, the report did not suggest significant improvements, stating that the primary endpoint regarding median overall survival had not yet been reached. Following this news, the value of ImmunityBio's shares dropped significantly, highlighting the financial impact of the misleading communications from the company's leadership. ## How to Participate The law firm encourages any investors who suffered losses during the identified period to reach out to them directly. The goal of participating in this class action is to seek a lead plaintiff who will guide the litigation on behalf of the entire class, ensuring that all affected investors have their voices heard in court. Investors can choose whether to become a lead plaintiff or remain an absent class member without affecting their ability to recover any potential damages. Furthermore, Faruqi & Faruqi is open to receiving information from anyone connected with ImmunityBio, including whistleblowers and former employees, to gather as much evidence as possible regarding the company's conduct. ## Contact Information For those interested in exploring this case further or seeking assistance, Faruqi & Faruqi provides the opportunity for potential plaintiffs to reach out to their office. Interested individuals can call Senior Partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310) for more details. Alternatively, additional information and updates about the class action can be found on their official website. ## Conclusion The upcoming deadline presents a crucial window for ImmunityBio investors to join the class action and advocate for their rights. Given the severity of the allegations against the company, affected parties are advised to take prompt action to ensure they can participate in any potential recovery from the claimed securities violations.